John F de Groot, MD, neuro-oncologist, The University of Texas MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

In a trial, mice were treated with altiratinib alone, bevacizumab alone, or a combination of the two agents. De Groot says the combination dramatically reduced tumor volume and tumor invasion.

De Groot speculates that the combination worked so well because it was able to block myeloid cell infiltration and reduce angiogenesis in order to decrease tumor cell invasion.

View more from the 2014 Society for Neuro-Oncology Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Brain Cancer

 Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Society for Neuro-Oncology Annual Meeting

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma